Page 6 - புனே சீரம் நிறுவனம் ஆஃப் இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Synopsis The study on the immune response to Covishield was carried out by researchers from New Delhi s CSIR-Institute of Genomics and Integrative Biology (IGIB), Max Super Speciality Hospital and Institute of Endocrinology, Diabetes and Metabolism as well as the Academy of Scientific and Innovative Research (AcSIR) in Ghaziabad. PTI Those who have recovered from COVID-19 respond faster to the Covishield vaccine and reach high antibody levels, says a study, leading to hopes that they may not need a second dose and therefore help widen India s corona immunisation cover. The study on the immune response to Covishield was carried out by researchers from New Delhi s CSIR-Institute of Genomics and Integrative Biology (IGIB), Max Super Speciality Hospital and Institute of Endocrinology, Diabetes and Metabolism as well as the Academy of Scientific and Innovative Research (AcSIR) in Ghaziabad.

Andhra pradeshUttar pradeshNew delhiVineeta balAnurag agrawalInnovative research acPune serum institute of indiaPune indian institute of science educationInstitute of endocrinologyAcademy of scientificIntegrative biologyMax super speciality hospitalInnovative researchSerum instituteBharat biotechIndian institute